CVS Earnings Beat Estimates, Guidance Holds

CVS earnings beat Q4 forecasts and affirmed 2026 adjusted EPS while trimming cash-flow to at least $9.0 billion, pressuring sector positioning.

February 10, 2026·2 min read
View all news articles
Flat vector pharmacy capsule with dimming glow signaling CVS earnings beat and trimmed cash-flow from Medicare seasonality.

KEY TAKEAWAYS

  • Q4 revenue was $105.7 billion and adjusted EPS $1.09, both beating consensus.
  • Affirmed 2026 adjusted EPS guidance of $7.00 to $7.20 while trimming cash flow to at least $9.0 billion.
  • Health Care Benefits had an adjusted operating loss of $676 million linked to Medicare Part D seasonality.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

CVS Health (CVS) beat fourth-quarter revenue and adjusted-profit forecasts on Feb. 10, 2026, affirming 2026 adjusted-EPS guidance while trimming its full-year cash-flow outlook. The company cited Medicare Part D seasonality and a weak Medicare Advantage rate outlook as key factors affecting results.

Results Beat While Guidance Holds Amid Cash-Flow Cut

CVS reported fourth-quarter 2025 revenue of $105.7 billion, up 8.2% year over year, and adjusted EPS of $1.09, both exceeding consensus estimates. Full-year revenue rose 7.8% to $402.1 billion, with adjusted EPS of $6.75 and GAAP diluted EPS of $1.39. Cash flow from operations reached $10.6 billion.

The company affirmed 2026 adjusted EPS guidance of $7.00 to $7.20 and a GAAP diluted EPS range of $5.94 to $6.14. However, it lowered its cash-flow-from-operations target to at least $9.0 billion from a prior goal of $10.0 billion or more. This revision reflects changes in Medicare Part D and the impact of the Inflation Reduction Act. The outlook assumes execution of a turnaround plan under Chief Executive David Joyner, who was appointed in late 2024. Joyner said, “Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses.”

Retail and PBM Drive Growth Despite Health Care Benefits Pressure

Retail Pharmacy revenue rose 12.4% year over year to $37.7 billion in the quarter, with same-store sales up 15.0%. Health Services revenue increased 9.0% to $51.2 billion. The company completed a transition to cost-based reimbursement across Commercial, Third-Party Discount, Medicare, and Medicaid channels. Aetna approved more than 95% of eligible prior authorizations within 24 hours.

The Health Care Benefits segment generated $36.3 billion in revenue, up 10.1% year over year, but recorded an adjusted operating loss of $676 million. CVS attributed the loss to Medicare Part D seasonality and the Inflation Reduction Act’s effects. The full-year medical benefit ratio stood at 91.2%.

On Jan. 27, 2026, the Centers for Medicare & Medicaid Services (CMS) proposed a 0.09% average Medicare Advantage payment increase for 2027, well below historical increases and analyst expectations. CMS’s rate outlook and risk-scoring reforms will affect Aetna’s reimbursement profile and add near-term pressure to Health Care Benefits results. The company linked these factors to its lowered cash-flow forecast.

The combination of Medicare Part D seasonality and the CMS rate outlook is central to CVS’s trimmed cash-flow projection and will materially influence near-term Health Care Benefits results and cash-generation assumptions.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

TeraWulf Q3 2026 Results Lifted by HPC Leases

TeraWulf Q3 2026 Results Lifted by HPC Leases

TeraWulf Q3 2026 results focus on HPC leases and Lake Mariner capacity and cite Google-backed Anthropic financing, shifting trader focus on execution risk.

Broadcom Stock Faces Volatility, Long-Term Case Stands

Broadcom Stock Faces Volatility, Long-Term Case Stands

Broadcom stock drew attention after commentary cited large cash generation and a December capital review, focusing traders on dividends and buybacks.

Hims & Hers Eli Lilly Deal Expands Access to Obesity Drugs

Hims & Hers Eli Lilly Deal Expands Access to Obesity Drugs

Hims & Hers Eli Lilly deal brings Zepbound and Foundayo to the platform at self-pay prices, widening GLP-1 access and reshaping Hims & Hers' commercial mix.

Fox Completes Roku Acquisition

Fox Completes Roku Acquisition

Fox completes Roku acquisition, reshaping Fox's capital base through cash-and-stock consideration and prompting investor shifts around streaming assets.

IREN Q1 FY27 Results Show AI Cloud Surge

IREN Q1 FY27 Results Show AI Cloud Surge

IREN Q1 FY27 Results show AI Cloud surge lifted revenue, backlog while a funded $4.0 billion contracted ARR moved to Jan 2027, tightening positioning.

DraftKings Q3 2026 Earnings Weaken on Predictions Spend

DraftKings Q3 2026 Earnings Weaken on Predictions Spend

DraftKings Q3 2026 Earnings saw revenue growth but a wider adjusted-EBITDA loss after Predictions investment, narrowing 2026 outlook and pressuring flows.